首页   >  
Protease/Metabolic Enzyme
  • Protease/Metabolic Enzyme
  >  
Factor Xa

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

Factor Xa

结构式 货号 产品名称 CAS号
Edoxaban 结构式
BCP38288 依度沙班 912273-65-5
Edoxaban is an orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Edoxaban is administered as edoxaban tosylate. This agent has an elimination half-life of 9-11 hours and undergoes renal excretion.
BMS-962212 结构式
BCP31167 BMS-962212 1430114-34-3
BMS-962212 is a reversible, direct, and highly selective inhibitor of FXIa.
BMS-740808 结构式
BCP23400 BMS-740808 280118-23-2
BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Betrixaban maleate 结构式
BCP25697 Betrixaban maleate 936539-80-9
Betrixaban is a highly potent, selective, and orally efficacious factor Xa inhibitor with IC50 of 1.2 nM(inhibition of Factor 10a).
Idraparinux sodium 结构式
BCP16293 艾屈肝素钠 149920-56-9
Idraparinux selectively blocks coagulation factor Xa.
Z-D-Arg-Gly-Arg-pNA   2 HCl 结构式
BCP18446 Z-D-Arg-Gly-Arg-pNA 2 HCl 113711-77-6
Z-RGR-pNA is a chromogenic substrate for the determination of factor Xa.
Letaxaban 结构式
BCP24734 Letaxaban 870262-90-1
Letaxaban, also known as TAK-442, is a potent, selective, and orally active factor Xa inhibitor, which is a tetrahydropyrimidin-2(1H)-one derivative.
D-PHE-PIP-ARG-PNA 结构式
BCP18445 D-PHE-PIP-ARG-PNA 115388-96-0
Thrombin substrates are often cleaved as well by trypsin and trypsin-like enzymes, e.g. I-1365, I-1560, J-1120, and L-1150. Chromogenic substrate specific for thrombin but insensitive to factor Xa.
Rivaroxaban Diol 结构式
BCP07255 利伐沙班二醇 1160170-00-2
Rivaroxaban is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
5-R-Rivaroxaban 结构式
BCP09021 5-R-利伐沙班 865479-71-6
5-R-Rivaroxaban is (R) enantiomer of Rivaroxaban. Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.
123下一页共 23 条记录 1 / 3 页 
2853530910